Incyte Corporation
INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor tā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$82.70
Price+1.27%
$1.04
1Y
Price
Market Cap
$16.149b
Large
Price/Earnings 3y Avg5y Avg
19.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+47.8%
EBITDA Margin+33.3%
Net Profit Margin+2.1%
Free Cash Flow MarginRevenue
$4.585b
+8.1%
1y CAGR+10.6%
3y CAGR+11.4%
5y CAGREarnings
$870.870m
+2570.2%
1y CAGR+850.3%
3y CAGR+621.7%
5y CAGREPS
$4.40
+2833.3%
1y CAGR+937.8%
3y CAGR+687.2%
5y CAGRBook Value
$4.171b
$5.821b
Assets$1.650b
Liabilities$42.408m
DebtDebt to Assets
0.7%
-
Debt to EBITDAFree Cash Flow
$945.583m
+279.6%
1y CAGR+61.8%
3y CAGR+60.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company